

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

April 02, 2026

To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	--

Dear Sir/Ma'am,

Sub.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition.

In continuation to our intimation dated November 13, 2025, we are pleased to announce Investment in Celliimune Biotech Private Limited with objective to advance pioneering research in DNA engineering for cancer therapeutics and to develop innovative alternatives to conventional chemotherapy.

The requisite details of terms of the provisions of Regulation 30 read with Schedule III and SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 are enclosed herewith.

This is for your information and records.

For Concord Biotech Limited

Paritosh Trivedi
Company Secretary & Compliance Officer
ACS 63623

Encl : As above

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	CELLIIMUNE BIOTECH PRIVATE LIMITED, (hereby referred as "Celliimune") Incorporated under Companies Act, 2013. Authorised Share Capital: Rs. 1,20,00,000 divided into 12,00,000 equity shares of Rs. 10 Each Issued share capital: Rs. 66,00,000 divided into 6,60,000 equity shares of Rs. 10 Each Turnover:- Celliimune Biotech Private Limited has Nil Turnover.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arm's length	Celliimune became a wholly owned subsidiary of Concord Biotech Limited. Prior to this acquisition, the Promoter / Promoter group held majority shareholding in the Company, and Mr. Ankur Vaid and Ms. Sonal Kumra serve as Directors of the Company. Therefore, the said investment falls under the purview of Related Party Transaction. This investment and subscription of shares was at arm's length basis. Yes, the promoter/ promoter group/ group companies are interested.
c)	Industry to which the entity being acquired belongs	Biopharmaceutical Industry
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To advance pioneering research in DNA engineering for cancer therapeutics and to develop innovative alternatives to conventional chemotherapy. The acquisition is going to help in innovating new therapy for treatment of cancer.

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

e)	brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable										
f)	indicative time period for completion of the acquisition	Acquisition completed on April 02, 2026										
g)	Consideration – whether cash consideration or share swap or any other form and details of the same;	Cash Consideration										
h)	Cost of acquisition and/or the price at which the shares are acquired;	Rs. 66,00,000/- (Rupees Sixty-six lacs only)										
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	100% in the equity of Celliimune Biotech Private Limited										
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Celliimune is working on developing technology for specializing in the discovery, development, and commercialization of novel cell and gene therapy solutions.</p> <p>Brief Details of Celliimune are as under:</p> <table border="1"><thead><tr><th>Particulars</th><th>Details</th></tr></thead><tbody><tr><td>Registration Number</td><td>U86905GJ2025PTC157943</td></tr><tr><td>Date of Incorporation</td><td>January 15 ,2025</td></tr><tr><td>History of last 3 years' Turnover</td><td>NIL</td></tr><tr><td>Country of Presence</td><td>India</td></tr></tbody></table>	Particulars	Details	Registration Number	U86905GJ2025PTC157943	Date of Incorporation	January 15 ,2025	History of last 3 years' Turnover	NIL	Country of Presence	India
Particulars	Details											
Registration Number	U86905GJ2025PTC157943											
Date of Incorporation	January 15 ,2025											
History of last 3 years' Turnover	NIL											
Country of Presence	India											